Canaccord analyst Susan Anderson lowered the firm’s price target on Prestige Consumer (PBH) to $88 from $100 and keeps a Buy rating on the shares. The firm said they posted solid results and management noted that sales and earnings exceeded expectations due to Clear Eyes supply timing and the timing of certain retailer orders, though this will come out of 3Q now.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PBH:
- Prestige Consumer Healthcare Reports Q2 Fiscal 2026 Results
- Prestige Consumer Healthcare’s Earnings Call Highlights Growth and Challenges
- Strong Performance and Positive Outlook: Buy Rating for Prestige Consumer Healthcare
- Prestige Consumer narrows FY26 adj EPS view to $4.54-$4.58 from $4.50-$4.58
- Prestige Consumer reports Q2 adjusted EPS $1.07, consensus 97c